One of the most intensively investigated molecular targets in oncology proves its therapeutic worth for thyroid eye disease. The first antibody drug targeting the insulin-like growth factor 1 receptor (IGF-1R) won regulatory approval in January — although not for the treatment of cancer, the indication first pursued more than a decade ago in some 30 different development programs involving experimental IGF-1R inhibitors. Instead, Horizon Therapeutics’ Tepezza (teprotumumab) became the first and only medicine approved by the US Food and Drug Administration for the treatment of thyroid eye disease (TED), a visionthreatening autoimmune disorder, also known as Graves’ orbitopathy, in which the fatty tissue and muscles around the eye become inflamed, pushing the eyeball outward.

Para acessar a publicação na íntegra clique aqui

Fonte: Nature Biotechnology | VOL 38 | April 2020 | 379–391 | www.nature.com/naturebiotechnology